Nektar Therapeutics segnala gli utili su base trimestrale. Questi report sugli utili trimestrali offrono agli investitori uno sguardo ai risultati finanziari di un'azienda per un periodo di 3 mesi. I report sugli utili includono quasi sempre i risultati EPS e i ricavi.
Analizza lo storico degli utili di Nektar Therapeutics utilizzando ordinamenti e filtri avanzati.
Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
NKTR | Nektar Therapeutics | -$2.66 | -$2.81 | -$1.87 | 33.45% | $24.12M | $10.35M | $11.79M | 13.91% | 11/06/2025 | |
NKTR | Nektar Therapeutics | -$3.75 | -$3.12 | -$2.95 | 5.45% | $23.49M | $9.96M | $11.18M | 12.18% | 08/07/2025 | |
NKTR | Nektar Therapeutics | -$2.85 | -$2.70 | -$3.60 | -33.33% | $21.64M | $15.61M | $10.46M | -32.99% | 05/08/2025 | |
NKTR | Nektar Therapeutics | -$3.30 | -$2.85 | -$2.25 | 21.05% | $23.89M | $36.66M | $29.18M | -20.42% | 03/12/2025 | |
NKTR | Nektar Therapeutics | -$2.85 | -$3.15 | -$2.70 | 14.29% | $24.14M | $18.28M | $24.12M | 31.97% | 11/07/2024 | |
NKTR | Nektar Therapeutics | -$4.05 | -$3.00 | -$3.75 | -25.00% | $20.50M | $17.54M | $23.49M | 33.92% | 08/08/2024 | |
NKTR | Nektar Therapeutics | -$3.75 | -$2.85 | -$2.85 | 0.00% | $21.59M | $15.34M | $21.64M | 41.06% | 05/09/2024 | |
NKTR | Nektar Therapeutics | -$4.80 | -$3.15 | -$3.30 | -4.76% | $22.02M | $18.05M | $23.89M | 32.33% | 03/04/2024 | |
NKTR | Nektar Therapeutics | -$4.65 | -$3.00 | -$2.85 | 5.00% | $23.63M | $21.31M | $24.14M | 13.30% | 11/07/2023 | |
NKTR | Nektar Therapeutics | -$12.75 | -$4.20 | -$4.05 | 3.57% | $21.59M | $21.83M | $20.50M | -6.10% | 08/08/2023 | |
NKTR | Nektar Therapeutics | -$7.35 | -$3.75 | -$3.75 | 0.00% | $24.82M | $19.84M | $21.59M | 8.84% | 05/09/2023 | |
NKTR | Nektar Therapeutics | -$11.85 | -$6.75 | -$4.80 | 28.89% | $25.01M | $22.13M | $22.02M | -0.48% | 02/28/2023 | |
NKTR | Nektar Therapeutics | -$10.50 | -$6.75 | -$4.65 | 31.11% | $24.92M | $22.61M | $23.63M | 4.49% | 11/03/2022 | |
NKTR | Nektar Therapeutics | -$10.35 | -$14.10 | -$12.75 | 9.57% | $28.33M | $22.66M | $21.59M | -4.74% | 08/04/2022 | |
NKTR | Nektar Therapeutics | -$10.20 | -$10.20 | -$7.35 | 27.94% | $23.65M | $24.38M | $24.82M | 1.81% | 05/05/2022 | |
NKTR | Nektar Therapeutics | -$9.75 | -$12.15 | -$11.85 | 2.47% | $23.46M | $25.33M | $25.01M | -1.27% | 02/28/2022 | |
NKTR | Nektar Therapeutics | -$9.15 | -$12.00 | -$10.50 | 12.50% | $30.03M | $27.87M | $24.92M | -10.58% | 11/04/2021 | |
NKTR | Nektar Therapeutics | -$6.75 | -$11.10 | -$10.35 | 6.76% | $48.85M | $25.98M | $28.33M | 9.05% | 08/05/2021 | |
NKTR | Nektar Therapeutics | -$7.95 | -$10.80 | -$10.20 | 5.56% | $50.57M | $26.90M | $23.65M | -12.09% | 05/06/2021 | |
NKTR | Nektar Therapeutics | -$9.60 | -$10.20 | -$9.75 | 4.41% | $33.86M | $30.01M | $23.46M | -21.82% | 02/25/2021 |
| Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
|---|---|---|---|---|
| Q3 | 2025-11-06 | $-1.87 | $-2.81 | 33.5 % |
| Q2 | 2025-08-07 | $-2.95 | $-3.12 | 5.45 % |
| Q1 | 2025-05-08 | $-3.60 | $-2.70 | -33.3 % |
| Q4 | 2025-03-12 | $-2.25 | $-2.85 | 21.1 % |
| Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
|---|---|---|---|---|
| Q3 | 2025-11-06 | $11.79M | $10.35M | 13.9 % |
| Q2 | 2025-08-07 | $11.18M | $9.96M | 12.2 % |
| Q1 | 2025-05-08 | $10.46M | $15.61M | -33.0 % |
| Q4 | 2025-03-12 | $29.18M | $36.66M | -20.4 % |
Nektar Therapeutics (NKTR) non ha ancora previsto report sulle performance. L'ultimo report sui risultati è stato pubblicato il novembre 6, 2025 per il Q3.
Nektar Therapeutics (NKTR) non ha ancora in programma alcun report sugli utili. L'ultimo report sugli utili è stato pubblicato il novembre 6, 2025 per il Q3 e l'EPS effettivo è stato $-1.87, che superato la stima di $-2.81.
Nektar Therapeutics (NKTR) non ha ancora pianificato alcun report sugli utili. L'ultimo report sugli utili è stato pubblicato il novembre 6, 2025 per il Q3 e i ricavi effettivi sono stati $11.8M, che superato la stima di $10.4M.
Sfoglia stime sugli utili, EPS e ricavi su tutte le azioni.